Stock analysts at StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ - Get Free Report) in a report issued on Tuesday. The firm set a "hold" rating on the medical research company's stock.
Enzo Biochem Price Performance
ENZ traded down $0.31 during trading on Tuesday, reaching $0.70. The stock had a trading volume of 1,730,476 shares, compared to its average volume of 107,512. The stock's 50 day moving average is $1.09 and its two-hundred day moving average is $1.11. Enzo Biochem has a one year low of $0.68 and a one year high of $1.50.
Enzo Biochem (NYSE:ENZ - Get Free Report) last issued its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.
Institutional Trading of Enzo Biochem
Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company's stock valued at $413,000 after buying an additional 11,742 shares during the last quarter. BBR Partners LLC purchased a new stake in Enzo Biochem during the third quarter valued at $112,000. XTX Topco Ltd lifted its holdings in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company's stock valued at $31,000 after acquiring an additional 13,735 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company's stock worth $2,725,000 after purchasing an additional 64,417 shares during the last quarter. 36.90% of the stock is currently owned by hedge funds and other institutional investors.
About Enzo Biochem
(
Get Free Report)
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Read More
Before you consider Enzo Biochem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzo Biochem wasn't on the list.
While Enzo Biochem currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
